Navigation Links
Arno Therapeutics Appoints William F. Hamilton to Board of Directors
Date:10/30/2008

FAIRFIELD, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI.OB), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the appointment of William F. Hamilton, Ph.D. to its Board of Directors and as chairman of the audit committee. Dr. Hamilton has over 40 years experience as a professor at The Wharton School with particular expertise in the areas of technology strategy and planning, entrepreneurship and technological innovation.

Dr. Hamilton, 69, has served on the University of Pennsylvania faculty since 1967, and is the Landau Professor of Management and Technology, and Director of the Jerome Fisher Program in Management and Technology at The Wharton School and the School of Engineering and Applied Science. As a co-founder and Director of Research, and later as Associate Director of the Institute of Health Economics, he led development of the interdisciplinary research program which was selected in nationwide competition as the National Center for Management Research in the health field. He serves as a director of NovaDel Pharma Inc., Avid Radiopharmaceuticals, Inc., Yaupon Therapeutics, Inc., Neuro Diagnostic Devices, Inc. and Neose Technologies, Inc. Dr. Hamilton received his B.S. and M.S. in chemical engineering and his MBA from the University of Pennsylvania, and his Ph.D. in applied economics from the London School of Economics.

Arie S. Belldegrun, M.D., FACS, Chairman of the Board of Directors of Arno, said, "Bill brings to Arno an impressive track record from a distinguished career in academia. We are confident that his extensive expertise in strategic management, technological innovation and entrepreneurship will be of great benefit to Arno's Board of Directors and senior management team."

Roger G. Berlin, M.D., Chief Executive Officer or Arno added "We are extremely pleased to welcome to our Board an executive with Bill's outstanding leadership abilities and expertise in technology development and innovation. Bill's insight into the complexities of biotechnology innovation and development will be invaluable in helping us achieve our strategic goals."

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
2. Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
3. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
4. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
5. Synvista Therapeutics Appoints William Federici to its Board of Directors
6. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
7. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
8. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
9. Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
10. Afid Therapeutics Inc.s New Anticoagulant Heparin Replacement Passes in Vivo Test
11. Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... Datos Health , developer of a pioneering Patient-Generated ... the largest Electronic Medical Records (EMR) provider in South Africa. By using Datos’ ... patient’s remote health progress, empowering the patient to take direct responsibility for their cost ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Miami native and ... a dentist. , “I could have never imagined back in 1991 that this journey ... Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant dentistry ...
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Medicine Technology: